Herman Verrelst

Herman Verrelst

Herman Verrelst

CEO - Biocartis

Herman Verrelst is CEO and Director of Biocartis. He is a seasoned executive with a proven international commercial track-record in molecular diagnostics. Before joining Biocartis in September 2017, he was active as Vice President and General Manager of the Genomics and Clinical Applications Division of Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets. In this role, Herman has been instrumental in the expansion of Agilent’s product portfolio through product innovations and new technologies, primarily in the area of precision genomics for oncology. He joined Agilent in May 2015 as General Manager of the Clinical Applications Division following Agilent’s acquisition of Cartagenia, of which Herman was CEO and founder. Cartagenia was a spin-off of Katholieke Universiteit Leuven (Belgium), focused on software solutions for clinical genetics and molecular oncology. Prior to that, Herman was CEO of Medicim, which was acquired by the Swiss-based Nobel Biocare AG in 2007, as well as founder and CEO of DATA4s, which was acquired by Norkom Technologies Ltd. in 2004. Herman holds a Master’s degree in Electrical Engineering (Katholieke Universiteit Leuven, Belgium).

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners